- Home
- EVV vs COLL Comparison
EVV vs COLL Comparison
Compare EVV & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVV
- COLL
- Stock Information
- Founded
- EVV 2003
- COLL 2002
- Country
- EVV United States
- COLL United States
- Employees
- EVV N/A
- COLL N/A
- Industry
- EVV Finance/Investors Services
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- EVV Finance
- COLL Health Care
- Exchange
- EVV Nasdaq
- COLL Nasdaq
- Market Cap
- EVV 1.2B
- COLL 958.8M
- IPO Year
- EVV N/A
- COLL 2015
- Fundamental
- Price
- EVV $10.19
- COLL $32.52
- Analyst Decision
- EVV
- COLL Strong Buy
- Analyst Count
- EVV 0
- COLL 4
- Target Price
- EVV N/A
- COLL $43.75
- AVG Volume (30 Days)
- EVV 323.7K
- COLL 304.4K
- Earning Date
- EVV 01-01-0001
- COLL 08-07-2025
- Dividend Yield
- EVV 9.66%
- COLL N/A
- EPS Growth
- EVV N/A
- COLL N/A
- EPS
- EVV N/A
- COLL 1.25
- Revenue
- EVV N/A
- COLL $664,283,000.00
- Revenue This Year
- EVV N/A
- COLL $20.04
- Revenue Next Year
- EVV N/A
- COLL $3.98
- P/E Ratio
- EVV N/A
- COLL $25.91
- Revenue Growth
- EVV N/A
- COLL 17.17
- 52 Week Low
- EVV $8.52
- COLL $23.23
- 52 Week High
- EVV $10.07
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- EVV 53.55
- COLL 69.85
- Support Level
- EVV $10.20
- COLL $30.60
- Resistance Level
- EVV $10.34
- COLL $33.22
- Average True Range (ATR)
- EVV 0.08
- COLL 0.85
- MACD
- EVV -0.00
- COLL 0.27
- Stochastic Oscillator
- EVV 50.33
- COLL 82.32
About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.